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Background. Our knowledge on long-term outcome in CAH remains incomplete. Methods. In a prospective study (33 CAH
patients, 33 age-matched controls), reproductive outcomes, self-rating of genital appearance and function, and sexuality were
correlated to degree of initial virilisation, genotype, and surgery. Results. Patients had larger median clitoral lengths (10.0mm
[range 2–30] versus 3.5 [2–8], P<. 001), shorter vaginal length (121mm [100–155] versus 128 [112–153], P = .12), lower
uterine volumes (29.1ml [7.5–56.7] versus 47.4 [15.9–177.5], P = .009), and higher ovarian volumes (4.4ml [1.3–10.8] versus 2.8
[0.6–10.8], P = .09) than controls. Satisfaction with genital appearance was lower and negatively correlated to degree of initial
virilisation (rs =≤ −0.39,P ≤ .05). More patients had never had intercourse (P = .001), and age at 1st intercourse was higher
(18yrs versus 16yrs, P = .02). Conclusion. Despite overall acceptable cosmetic results, reproductive outcomes were suboptimal,
supporting that multidisciplinary teams should be involved in adult follow up of CAH patients.
1.Introduction
Congenital adrenal hyperplasia due to 21-hydroxylase deﬁ-
ciency is an autosomal recessive disorder characterized by
impaired or total loss of activity in the enzyme required
for cortisol and aldosterone production, resulting in highly
increased adrenal androgen synthesis [1]. Depending on
the severity of the underlying defect in CYP21,f e m a l e
CAH patients show varying degrees of genital virilisation.
Ambiguous genitalia in the newborn, severe clitoromegaly,
and vaginal stenosis may require many diagnostic and
surgical procedures, not only initially, but also repetitively
during adolescence. Despite an increasing focus on optimal
treatment of CAH patients, our knowledge of long-term
outcomes of this condition remains incomplete. Thus, the
aim of the present study was to evaluate gynecological and
reproductive outcomes in a group of women diagnosed
with CAH due to 21-hydroxylase deﬁciency in childhood or
adolescence.
2.MaterialsandMethods
2.1. Population Characteristics
2.1.1. Patients. This study was part of a follow-up study
of adult female patients diagnosed with disorders of sex
development (DSD) at the University Hospital of Copen-
hagen (Rigshospitalet) from 1953–2003. Participation rate
was 81%. In total, 33 CAH patients with genetically ver-
iﬁed CYP21 deﬁciency were included (30 yrs, 19–52). As
previously reported [2, 3], patients with CYP21 deﬁciency
were divided according to the clinical data and the predicted2 International Journal of Pediatric Endocrinology
severity of the mutation [4] into salt-wasters (SW, n = 21),
simple-virilizers (SV, n = 6), and late-onset (LO, n = 5) CAH.
One patient was ﬁrst diagnosed in adolescence and was in
the present study included in the group of patients with late-
onset CAH.
Diagnosis of CAH patients occurred at a median age of
0 yrs (0–16 yrs). At birth, seven patients with salt-wasting
CAH were assigned male gender, but with a reassignment
to females during the ﬁrst months of life, while ten salt-
wasters and two simple-virilizers with ambiguous genitalia
at birth were assigned female gender. Data on virilisation
at birth was missing in two patients. In the patients, the
degree of virilisation at the time of diagnosis was graded
from 1 (lowest) to 5 (highest): (1) none; (2) virilisation
diagnosed ≥1 year of age; (3) virilisation diagnosed <1y e a r
ofage;(4)ambiguousgenitaliaatbirth;(5)severevirilisation
with male gender assignment at birth, but reassignment to
female after diagnosis. In ﬁve patients, signiﬁcant urogenital
comorbidity included unilateral ureteronephrectomia due
to a malformed kidney and hydronephrosis, hysterectomy,
unilateral ovariectomy due to cysts, unilateral salpingo-
oophorectomyduetopyosalpinx,andsalpingectomyafteran
extrauterine pregnancy. Additionally three patients reported
urine incontinence.
2.1.2. Controls. A control group was recruited through the
Danish Civil Registration System. For each patient, twenty
women living in the Copenhagen area and born in the same
month and year as the patient were contacted by a letter. The
control with the closest match for self-reported education
was selected for pair-wise matching. Participation rate was
37%. One control person had a duplication of the ureter and
two had cervical conisations performed.
2.2. Assessment Program. Data were collected via medical
records and a structured interview. Satisfaction with genital
appearance and function was graded on an analogous 1–7
scale, with 1 representing not satisﬁed,4partly satisﬁed,a n d7
satisﬁed. If participants were unable to answer, answers were
treated as missing data.
The gynecological examination included measurements
of clitoral length (mm), and maximal vaginal length and
diameter measured with Hegar instruments (mm, maximal
vaginal width assigned ≥30mm). Uterine and ovarian
size was determined by transvaginal ultrasonography with
v o l u m e sc a l c u l a t e da sa ne l l i p s o i d[ 5]: volume (ml) =
4/3 ∗ Π ∗ length (cm) ∗ width (cm)2∗ 1/8. The mean
value of the two ovaries was presented (n = 31), unless
only one was visualized at ultrasound (n = 8). Six patients
declined gynecological examination, and four patients had
no gynecological examination performed due to logistical
reasons. In two controls, measurements were excluded due
to ongoing pregnancy.
The degree of hirsutism was graded according to the
modiﬁed Ferriman-Gallwey score [6, 7], in which nine body
areas were graded from minimal (grade 1) to frank hirsutism
(grade 4), 0 indicated absence of hirsutism. Five patients
declined to participate in this examination. Body mass index
(BMI) was calculated as weight (in kilograms) divided by
height (in meters) squared. Height was determined by a
Harpenden stadiometer (Holtain Ltd, Crymych, UK) to
the nearest 0.1cm, and weight was measured on a digital
weight scale with a precision of 0.1kg (SECA delta, model
707, SECA, Bradford, MA, USA). BMI measurements were
excluded in the pregnant controls.
Hormone analysis parameters, which were not correlated
tocycleday,includedandrogenstatusandantim¨ ullerianhor-
mone (AMH). The androgen status included serum testos-
terone, serum androstendione, and serum dihydrotestos-
terone (DHT), which were analyzed as described by
Lykkesfeldt et al. [8], and serum dehydroepiandrosterone
sulphate (DHEAS), which was measured by a radioim-
munoassay. For testosterone, androstenedione and DHT,
the intra- and interassay coeﬃcients of variation were
5% and <10%, respectively, with a limit of quantiﬁcation
of 0.1nmol/L, while intra- and interassay coeﬃcients of
variation of DHEAS were 7% and 10%, respectively, and the
limit of quantiﬁcation was 100nmol/L. The concentration
of serum AMH was measured by an ultrasensitive sandwich
enzyme immunometric assay using the EIA AMH/MIS kit
(Immunotech A11893, Beckman Coulter, Marseille, France).
For AMH, the intra- and interassay coeﬃcients of variation
were 7.8% and 11.6%, respectively, and the limit of detection
was 2pmol/L.
2.3. Statistical Analyses. Nonparametric statistical analy-
sis was used. The Mann-Whitney test with the Monte
Carlo exact test was used in comparisons of patients and
unmatched controls, the Wilcoxon signed rank sum test
was used in comparisons of patients and matched controls,
and the Kruskal-Wallis test in analysis of CAH subgroups.
Correlations were done by Spearman correlation. Data are
presented as medians (ranges), unless otherwise stated.
2.4.Approvals. Approvalsweregrantedfromthelocalethical
committee (01-051/01, 11-075/03), and the Danish Data
Registry (2001-41-0689). The study was performed accord-
ing to the Helsinki declaration II after written consent from
the participants.
3. Results
Clitoral operations had been performed in 27 CAH females,
including reduction with preservation of the glans (SW: n
= 16, SV: n = 5, LO: n = 1) and amputation (SW: n = 4,
SV: n = 1). Five SW-patients and 1 SV-patient had clitoral
operations performed twice. Age at ﬁrst clitoral operation
was 4.4 years (range 0.8–25 yrs). Clitoral length was larger
in CAH patients (10mm [2–30mm]) than in controls
(3.5mm [2–8mm]), P<. 001; see Figure 1. In patients,
no associations were observed between clitoral length or
clitoral surgery procedures and androgen levels, respectively,
(data not shown). Serum-antim¨ ullerian hormone (AMH)
correlated inversely with clitoral length (rs =− 0.59, P =
.01). No signiﬁcant correlation to surgery or number of
surgical procedures at clitoris was found (P = .22 and .13,
resp.), but age at clitoral surgery was inversely related to
serum-AMH levels (rs =− 0.57, P = .01).International Journal of Pediatric Endocrinology 3
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Figure 1: Gynecological outcomes in patients with congenital adrenal hyperplasia (CAH) and in controls: clitoral length (mm), vaginal
length (mm), uterine volume (ml) separated by primipara/multipara (+) or nullipara (–), and ovarian volume (ml) separated by current (+)
or no (–) use of hormonal contraception. Lines indicate median values.
Table 1:Satisfactionwithappearanceandfunctionofexternalgenitalia(meanandranges,1:lowestto7:highest)inpatientswithcongenital
adrenalhyperplasiaandincontrols.Signiﬁcancelevelsfordiﬀerencesbetweenpatientsandcontrolsareindicatedas
∗P <. 05and
∗∗P <. 01.
Controls CAH patients
All Clitoral reduction Clitoral resection
Clitoral appearance 6.8 (5–7) 5.8 (1–7)∗∗ 6.0 (4–7) 4.8 (1–7)
Clitoral function 6.9 (6-7) 6.2 (1–7)∗ 6.2 (2–7) 5.4 (1–7)
Vaginal appearance 6.6 (4–7) 5.9 (1–7) 6.1 (1–7) 4.8 (1–7)
Vaginal function 6.5 (3–7) 6.0 (1–7) 6.4 (1–7) 5.0 (1–7)
V a g i n a lo p e r a t i o n sh a db e e np e r f o r m e di n2 4C A H
patients, and patients were operated once (SW: n = 4, SV:
n = 2, LO: n = 1), twice (SW: n = 9, SV: n = 2), three times
(SW: n = 4), four times (SW: n = 1), or ﬁve times (SW: n
= 1), respectively. Vaginal operations included vaginoplasty
with skin transplants from the thigh, buttock, perineum or
labiae (SW: n = 18, SV: n = 2) or without skin transplants
(SV: n = 1, LO: n = 1). Adequate data on vaginoplasty was
missing in two patients (SW = 1, SV = 1). Age at ﬁrst vaginal
operationwas14.1years(range1.0–27.3).Vaginallengthwas
nonsigniﬁcantly shorter in patients (121mm [100–155mm]
than in controls (128mm [112–153]), P = .12; see Figure 1.
Thirty-six percent of the patients had a vaginal diameter
below 30mm, as compared to 6% in the control group. No
signiﬁcant correlations were found in vaginal measurements
and/or vaginal surgical procedures versus AMH-levels and
androgen levels, respectively (data not shown).
In contrast to controls, signiﬁcantly lower rating on
genital outcome was reported in CAH patients with respect
to clitoral appearance (P = .003) and clitoral function
(P = .02), and nonsigniﬁcantly lower ratings were reported
for vaginal appearance (P = .0 8 )a n df u n c t i o n( P = .32),
respectively; see Table 1. These ﬁndings were independent of
whether the patient had been operated or not. However, as
showninTable 1,nonsigniﬁcantlylowerratingsaftersurgical
clitoral resections than clitoral reductions were observed. No
signiﬁcant correlations were found between age at surgery
and rating of genitalia (data not shown), except a higher
satisfaction with clitoral function the younger the age at
surgery (rs =− 0.45, P = .03). In patients, vaginal
ratingscorrelatedpositivelytovaginaldiameter(appearance:
rs = 0.47 [P = .03]; function: rs = 0.42 [P = .08]).
Vaginalanatomyandfunctionwereratedbypatientswithout
transplants 7, that is, satisﬁed, while clitoral anatomy and4 International Journal of Pediatric Endocrinology
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Figure 2 :S e r u ml e v e l so fa n t i m ¨ ullerian hormone (AMH) in
patientswithcongenitaladrenalhyperplasia(CAH)andincontrols.
Lines indicate median values.
function in one patient was rated 6 and 2, respectively, and
in the other as 7, respectively. Satisfaction with clitoral and
vaginal appearance correlated negatively with the degree of
virilisation at time of diagnosis (rs =− 0.38 [P = .05] and
rs =− 0.39 [P = .04]).
The CAH patients had smaller uterine volume (median
29.1ml [range 7.5–56.7ml]), as compared to the healthy
controls (47.4ml [15.9–177.5]), P = .009, Figure 1.I n
nullipara patients, uterine volumes (median 24.1ml [7.5–
44.6],n=11)weresmallerthaninthecontrolgroup(median
45.7ml [15.9–67.0], n = 14), P = .006. There were no signiﬁ-
cant diﬀerences in uterine volumes in primipara/multipara
patients (median 41.9ml [25.6–56.7], n = 5) versus their
controls (median 66.6ml [25.6–177.5], n = 13), P = .59.
No associations were observed between uterine volume and
androgen- or AMH-levels (data not shown).
A nonsigniﬁcant larger median ovarian volume was
observed in the CAH group (4.4ml [range 1.3–10.8ml],
n = 13), as compared to the controls (2.8ml [0.6–10.8],
n = 26), P = .09; see Figure 1. In the patients no associations
were observed between ovarian volume and androgen- or
AMH-levels (data not shown). There were no signiﬁcant dif-
ferences in levels of serum-AMH between patients (median
11.0pmol/L [1–36]) and controls (13.0pmol/L [1–45]),
P = .16; see Figure 2. The AMH-levels in SW-, SV- and
LO-patients of 11.0pmol/L (1–36), 6.5pmol/L (1–21), and
15pmol/L (9–27), respectively, did not diﬀer between CAH
subgroups (P = .58). The age at menarche was signiﬁcantly
later in patients (14.8 years, 9.0–19.8) than in controls (13.0
years 10.0–15.5), P = .001.
CAH females had signiﬁcantly higher hirsutism scores
than matched controls (2.0 [0–12] versus 0.0 [0–11],
P = .001). In CAH subgroups hirsutism scores were SW =
2.0 [0–12], SV = 2.0 [1–4], and LO = 2.0 [0–9], reaching
statistical signiﬁcance in salt-wasters versus their controls
(P = .01). In CAH patients, positive correlations were
observed between hirsutism and serum levels of testosterone
(rs = .42, P = .03) and DHT (rs = .55, P = .003),
respectively, while no signiﬁcant correlation was observed
to serum androstenedione (rs = .35, P = .08) and serum
DHEAS (rs = .16, P = .45). Hirsutism did not correlate
to serum AMH-level (data not shown). BMI did not diﬀer
betweenpatients(25.0[20.6–42.8])andcontrols(26.7[18.7–
39.5]). A positive correlation was found between hirsutism
score and BMI in patients alone (rs = 0.36, P = .06)
and when grouped together with the controls (rs = 0.26,
P = .05).
Ascomparedtothecontrols(n=1),asigniﬁcantlyhigher
proportionofthepatients(n =13)hadneverhadintercourse
(P = .001), and age at 1st intercourse was higher (18 years
[14–35] versus 16 years [13–19], P = .02). In general, age
at 1st intercourse increased from nonclassical CAH (14 years
[14–22] to classical CAH; i.e., SV: 18 years [16–20] and SW:
19years[16–35]).Bothparameterswerepositivelyassociated
with the degree of virilisation at birth (rs = .34, P = .06, and
rs = 0.52, P = .02, resp.). Lack of intercourse was inversely
correlated with vaginal diameter (rs =− 0.70, P<. 001),
whether or not the patient had been operated (P = .04), and
positively with the number of vaginal operations (rs = 0.37,
P = .03), while no associations were observed for vaginal or
clitoral lengths or surgery of clitoris. Previous contact to a
sexologist was reported in two CAH females and in none of
thecontrols.However,aneedforcounsellingwasreportedin
seven CAH patients, and one control.
4. Discussion
The present study revealed signiﬁcant diﬀerences in the
size of internal and external genitalia between patients
with congenital adrenal hyperplasia due to 21-hydroxylase
deﬁciency and healthy women. The overall cosmetic results
were satisfactory for the majority of patients. However, the
lower rating of genital appearance and function in patients
appeared to inﬂuence their sexual life.
In this study, the clitoral operations diﬀered in type
and number. The diﬀerent surgery techniques may reﬂect
historical trends, as clitoridectomy has been replaced by
nerve-sparing clitoral reductions in the last decades [9].
Six CAH patients were operated twice. In one of these
patients, the initial operation comprised a corporeal sparing
clitoroplasty, while a reduction was performed in the second
operation. However in the other patients, reoperation may
have been performed because of regrowth of the clitoral
corpora during exposure to high androgen levels either
due to noncompliance or nonoptimal treatment. Current
androgen levels were not correlated to any of the gyneco-
logical outcomes. This may be explained by the fact that
current androgen status is highly dependent on current
medical treatment and compliance of treatment of the CAH
women whereas the herestudied outcome parameters are
moreinﬂuencedbyprenatalorearlypostnatalandrogenlevel
andlong-termtreatmentsuccess.Insomepatients,androgen
levels at the time of study entry were in fact suppressed
to lower than normal values. In general, the patients had
a vaginal depth within normal limits, but there was still a
tendency to avoid or delay intercourse. Long-term surgical
outcomes in patients with disorders of sexual development
includingCAHhavereacheddiscrepantconclusions[10,11].International Journal of Pediatric Endocrinology 5
It has been debated whether the optimal timing of surgery is
in early infancy, during puberty, or as some patient support
groups currently advocate when the patient can actively
participate in the decision.
Our study demonstrated a signiﬁcantly lower uterine
volume in CAH women than in healthy controls, which
was not completely ameliorated after successful pregnancy.
The compromised uterine growth may reﬂect an imbalance
between estrogens and androgens during adolescence, which
additionally may contribute to the reported delayed time
at menarche as seen in this study. Also a prenatal excess
of androgens may aﬀect uterine development permanently.
In Turner syndrome, uterine hypoplasia is reported [12],
and achievement of normal uterine growth during hormone
replacement therapy in adolescence and early adulthood is
likewise diﬃcult. A suboptimal uterine development may
contribute to the lower fertility rates seen in CAH females
[13, 14], and may be associated with a higher prevalence of
miscarriage and premature birth.
CAH patients had slightly larger ovarian volumes than
their controls. This may reﬂect a higher prevalence of
polycystic ovary syndrome, PCOS [15]; thus, both polycystic
ovaries [16] and insulin resistance [17, 18]h a v eb e e n
reported in CAH. However, in the present study, a suspicion
of PCOS was not supported by elevated serum levels of
antim¨ ullerian hormone in the patients. In fact, AMH levels
in our CAH patients tended to be lower than in age-matched
controls and were associated with the degree of initial
virilisation. Thus, it is tempting to speculate that prenatal
androgenexcess may reducethe number ofpreantral follicles
in the ovary and thereby ovarian reserve in CAH patients.
Clitoral length may be a marker of prenatal androgen
levels, and thus, the observed inverse correlation between
AMH levels and clitoral length additionally may indirectly
reﬂect an inverse correlation between AMH and prenatal
androgen excess. Prenatal androgen excess may contribute
to the reduced fertility rates of CAH patients, which was
also previously reported in our study group [3]. Hirsutism
correlated to current serum levels of testosterone and DHT,
but not to current AMH levels. Hirsutism mostly reﬂects
hyperandrogenism, whereas AMH is more likely more
related to the prenatal ovarian development and thereby the
existing ovarian follicle pool than to current testosterone
levels. Given the degree of hirsutism and delayed menarche,
the patients most likely have been exposed to longer periods
of hyperandrogenaemia, which may either be of adrenal or
ovarian origin [19]. Ovarian hyperandrogenism in classic
CAH is reported to result from perinatal masculinization of
the hypothalamic-pituitary-ovarian axis [20]. With a BMI
within the range of overweight [21], obesity in the CAH
patients, and especially the higher risk of obesity in CAH
children as compared to the background population [22],
mayfurtheraggravateahyperandrogeniccondition.Another
explanation for larger ovarian volumes in the CAH patients
may be ovarian adrenal rest tumours, which may originate
from pluripotent cells [23]. As the adrenals develop in the
immediate vicinity of the gonads, some adrenal tissue may
adhere to the gonads, and thereby descent with the testis or
the ovary [24]. Adrenal rest tumours in female CAH patient
have been inconsistently reported [25, 26], but are a well-
known phenomenon in male patients, in whom they may be
associated with a risk of subfertility [27, 28]. Unfortunately,
our ultrasound equipment was not sensitive enough to allow
detailed description of ovarian morphology.
We observed no signiﬁcant correlations between current
serum-antim¨ u l l e r i a nh o r m o n el e v e l sa n dv a g i n a lm e a s u r e -
ments, uterine volume and ovarian volume, respectively.
A possible explanation for the lacking correlation between
these gynecological parameters and serum levels of AMH
may include that the study group is small compared to large
biological variation in vaginal, uterine and ovarian param-
eters. We have no obvious biological explanation for the
observed inverse correlation between serum concentrations
of AMH and age at clitoral surgery, which therefore needs to
be supported by other studies.
Although around ninety percent of patients expressed
satisfaction, especially clitoral appearance was rated sig-
niﬁcantly lower in patients than in controls, and more
pronounced after clitoral resections than clitoral reductions.
Furthermore, the initial degree of virilisation at birth was
directly associated with older age at 1st intercourse and
lower cosmetic rating. Dissatisfaction with genital outcome
in 46,XY-females with micropenis reared as females [29],
and sexual diﬃculties in DSD-patients including CAH [30],
and in 46,XY-females after clitoral amputations compared to
other types of clitoral operations [31], has been reported.
Thus, it appears that the more conservative approach to
clitoral surgery is generally better perceived by patients than
previous clitoridectomies. A tendency for higher satisfaction
with clitoral function was observed the younger the age
at clitoral surgery. This may reﬂect that not only the type
of surgery, but also the timing of surgery is important for
development of the body image. This observation may thus
add an important aspect to ongoing debates about the best
timing of genital surgery from a medical and psychological
view point. In the present study, the physician who collected
the data was not the patients’ usual consultant. Therefore
we believe that there was no obvious compulsion to rate
artiﬁcially high, and our results reﬂect the patients’ true
opinion.
As compared to healthy controls, a larger proportion
of patients had never been engaged in intercourse, and age
at 1st intercourse increased with increasing severity of the
mutation. Similar ﬁndings have been reported, comparing
CAH females to healthy controls [14, 32] and to nonaﬀected
sisters [33], respectively. Only a small subgroup of patients
had undergone sexological counseling, but a signiﬁcant
proportion of patients reported that they would like such
counseling. It has been suggested that such counseling
should start from preadolescence, when most girls need
information about their condition to cope with hormone-
replacement therapy and often vaginoplasty or dilatation
[34]. Thus, in the present study, lack of intercourse was
more frequent in women who were operated with a positive
correlation to the total number of vaginal operations, and an
inverse correlation to vaginal diameter. These observations
strengthen the need of counseling, and it may also be
advantageous that such counseling was available during6 International Journal of Pediatric Endocrinology
adult life. To our knowledge no data exist about long-term
outcome of vaginal operations over the entire life span of
sexual activity.
Limitations of this study include that six patients
(SW = 4, SV = 2) declined gynecological examination, and
gynecological examination was not performed in four SW-
patients due to logistical reasons. We cannot exclude that
especially the patients’ refusal for examination may have
causedabiastowardsabetteroutcome.Furthermore,despite
the matching with controls for age and school education,
we cannot completely exclude selection bias: patients were
recruitedfromauniversity hospital andmaythereforenot be
representative for the entire CAH population. Additionally,
the medical and surgical care of the included patients spans
over several decades in which there have been signiﬁcant
changes in standard of care. Thus, our results may not be
applicable to current treatments. The lower participation
rate in the healthy controls may have introduced a bias
towards inclusion of either controls with poorest outcomes
(thereby giving the lowest estimate of diﬀerence between
patients and controls) or controls with best outcomes
(thereby overestimating the real diﬀerence between patients
and controls). We have no data on nonparticipants among
controls and are therefore unable to analyze this bias.
5. Conclusion
In the present study, long-term cosmetic and functional
reproductive outcomes of women with congenital adrenal
hyperplasia due to 21-hydroxylase deﬁciency were subop-
timal. Prenatal hormonal and genetic factors may con-
tribute to these outcomes, but better counseling of patients
throughout adult life may improve long-term satisfaction.
Given the complexity of CAH conditions, our ﬁndings sup-
port international recommendations that specialized multi-
disciplinary teams should be involved in the follow-up of
these patients, not only during childhood and adolescence,
but also during adult life.
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